Millions of people are suffering and dying from acute respiratory infections (such as pneumonia) and millions more suffer with life-long debilitating chronic diseases (such Chronic Obstructive Pulmonary Disease, Emphysema and Cystic Fibrosis).

There is an urgent need for more effective treatments for such people.

Haemair’s mission is the development of devices that could reduce morbidity and mortality from acute lung damage and enhance the lives of chronic sufferers from lung disease.

Haemair is developing medical devices that deliver oxygen directly to blood, thereby augmenting the reduced capacity of the lungs in sufferers from acute and chronic lung disease.






Haemair Oxygenator
Haemair Team
Haemair Life Support



Our technology will also include a control capability to match oxygenation to demand of the body – allowing mobility to patients under treatment. 

The company holds relevant granted patents for these innovative developments.

The initial Haemair product is a development of established Extracorporeal Life Support (ECLS/ECMO) technology and will be used to treat patients recovering from:  

• Cardiopulmonary surgery.

• Acute Respiratory Syndrome.

• Acute pneumonia.

• Acute pulmonary trauma. 

• Severe cardiac failure.